Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech, Xoma end Raptiva RA trial

DNA and XOMA terminated a Phase II trial of Raptiva efalizumab to treat

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE